Bone Biologics Corp Cash Flow-to-Debt Ratio
Bone Biologics Corp cash flow-to-debt ratio. Bone Biologics Corp (BBLG) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2026, meaning its operating cash flow of $-518.44K could theoretically repay -1% of its total liabilities ($512.02K) in one year. Check BBLG operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Bone Biologics Corp (2012–2025)
Cash flow-to-debt ratio of Bone Biologics Corp from 2012 to 2025. Historical debt coverage capacity for Bone Biologics Corp across 14 annual periods. Also explore Bone Biologics Corp (BBLG) net asset momentum to track the company's year-over-year net asset growth rate.
Bone Biologics Corp Cash Flow-to-Debt Ratio by Year (2012–2025)
Bone Biologics Corp cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for Bone Biologics Corp. For the full cash flow conversion analysis, see BBLG cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.43x | $-2.69 Million | $418.59K | ▲ +41.1% |
| 2024 | -10.92x | $-4.12 Million | $377.71K | ▲ +5.0% |
| 2023 | -11.49x | $-9.56 Million | $831.40K | ▼ -721.0% |
| 2022 | -1.40x | $-3.57 Million | $2.55 Million | ▲ +88.6% |
| 2021 | -12.30x | $-1.23 Million | $99.91K | ▼ -39338.3% |
| 2020 | -0.03x | $-426.93K | $13.69 Million | ▲ +88.6% |
| 2019 | -0.27x | $-3.25 Million | $11.90 Million | ▲ +35.8% |
| 2018 | -0.43x | $-4.10 Million | $9.64 Million | ▼ -17.5% |
| 2017 | -0.36x | $-3.33 Million | $9.19 Million | ▲ +52.5% |
| 2016 | -0.76x | $-7.33 Million | $9.61 Million | ▼ -67.0% |
| 2015 | -0.46x | $-3.55 Million | $7.76 Million | ▼ -24.7% |
| 2014 | -0.37x | $-2.76 Million | $7.52 Million | ▼ -34024.3% |
| 2013 | 0.00x | $-6.12K | $5.70 Million | ▲ +98.9% |
| 2012 | -0.10x | $-447.00 | $4.68K | — |